Aug 24 (Reuters) - The European Commission on Thursday approved U.S. drugmaker Pfizer's (PFE.N) vaccine for respiratory syncytial virus (RSV) to protect both babies and older adults in the ...

Pfizer PFE announced that the European Commission has approved its new vaccine, Abrysvo, for the prevention of respiratory syncytial virus (RSV) in infants through immunization of their pregnant ...

The European Medicines Agency (EMA) and the European Centre for Disease Control (ECDC) recommend targeting people at risk in ...

New Scientist explains how the latest covid-19 booster vaccines are different from previous ones, and who should get them ...

GSK plc (GSK, GSK.L) said Japan's Ministry of Health, Labour and Welfare has approved Arexvy for the prevention of respiratory ...

U.S. health officials are recommending RSV vaccinations for moms-to-be as a second option to protect newborns. The Centers ...

Updated COVID-19 vaccines are being rolled out in the U.S., aimed at targeting the latest, prevalent variants of the disease.

The shot will help shield newborns from RSV in the early months of life, when they're especially vulnerable to severe illness ...

(Alliance News) - GSK PLC on Monday said the Japan Ministry of Health, Labour & Welfare has approved Arexvy for adults over 60. Arexvy is a vaccine used for the prevention of respiratory syncytial ...

Women may soon have a vaccine they can take during a pregnancy to help protect their newborn from respiratory syncytial virus ...

London open The FTSE 100 is expected to open 30 points lower on Monday, having closed up 0.07% on Friday at 7,683.91.

U.S. health officials are recommending RSV vaccinations for moms-to-be as a second option to protect newborns.